Comparative Pharmacology
Head-to-head clinical analysis: NORDETTE 28 versus NORINYL 1 35 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORDETTE 28 versus NORINYL 1 35 21 DAY.
NORDETTE-28 vs NORINYL 1+35 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
One tablet orally once daily for 28 consecutive days.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean 17 hours); Levonorgestrel: 11-45 hours (mean 24 hours); clinical context: steady-state reached after 5-7 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady state achieved by day 10-14.
Renal: ~50% as metabolites, ~20% unchanged; Fecal: ~30% as metabolites; Biliary: minimal.
Renal (50-60% as metabolites, primarily glucuronide and sulfate conjugates) and fecal (30-40% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive